氟尿嘧啶植入剂治疗恶性胸腹水的药代动力学研究  

Study on pharmacokinetics of fluorouracil sustained release implant in the treatment with malignant pleural or peritoneal effusions

作　　者：洪艳艳[1] 陈振东[1] 张明军[1] 俞敏[2] 吴秀伟[1] 叶瑞萍[1] 刘利炜[1] 杨扬[1] 

机构地区：[1]安徽医科大学第一附属医院肿瘤科,合肥230022 [2]合肥工业大学控释药物研究室,合肥230009

出　　处：《中国临床药理学杂志》2009年第4期298-301,共4页The Chinese Journal of Clinical Pharmacology

基　　金：安徽省自然科学基金资助项目(060131227B)

摘　　要：目的研究氟尿嘧啶(5-Fu,抗癌药)植入剂治疗恶性胸腹水的药代动力学特点。方法入组12例恶性胸腹水患者,胸腹腔内植入氟尿嘧啶植入剂1500mg,定时取胸腹水及外周血样,高效液相色谱法测定5-Fu浓度,计算药代动力学参数。结果胸腹水药物浓度高,血药浓度低,2者比较差异显著(P<0.05)。在胸腹水中,药物浓度下降很慢,15天左右仍可维持有效浓度。结论氟尿嘧啶植入剂腔内植入后,局部药物浓度高,作用时间长。Objective To investigate the pharmacokinetics of fluorouracil （5 - Fu） sustained release implant （FSRI） administered intrapleural- ly or intraperitoneally in the patients with malignant pleural effusions or ascites. Methods Twelve patients with moderate or large malignant pleural effusions or ascites were enrolled. FSRI was administered intrapleurally or intraperitoneally at a fixed dosage of 1500 mg. The pleural or peritoneal effusions and plasma samples were obtained before and after administration. Concentrations of 5-Fu were measured by HPLC. Pharmacokinetic parameters were calculated. Results In the pleural（peritoneal） effusions, 5 - Fu concentration was significantly higher than that in plasma （P 〈 0.05 ）. Drugs released slowly, and the concentrations in the effusions were still more than the effective concentration at the 15th day. Conclusion When administered intrapleurally or intraperitoneaUy fluorouracil sustained release implant had a long elimination and high local concentrations.

关 键 词：氟尿嘧啶缓释制剂 药代动力学 恶性胸腔积液 恶性腹腔积液 

分 类 号：R969.1[医药卫生—药理学] R979.1[医药卫生—药学]